The prevalence of drug-resistant pulmonary tuberculosis (DR-TB) in India, particularly Multidrug-resistant
and Rifampicin-resistant TB (MDR-TB and RR-TB), poses a significant challenge to the country's efforts in
controlling and eliminating the disease. The high incidence of FLQ-R in MDR-TB cases further complicates
management and leads to poor outcomes. The implementation of Shorter Course Chemotherapy (SCC) for
MDR-TB, including all-oral regimens, faces uncertainties in the Indian context due to the high prevalence of
FLQ-R, limited healthcare system capacities, and challenges in detecting resistance. The BPaLM regimen
recommended by the WHO for MDR/RR-TB cases, including those with FLQ-R, may be a more suitable option
for India. However, the feasibility and appropriateness of newer regimens in the Indian setting require careful
evaluation, along with the development of tailored strategies and guidelines to optimize treatment outcomes
and prevent the development of further drug resistance. Addressing these complexities is crucial for the
success of India's National Tuberculosis Eradication Program and the overall management of DR-TB in the
country.
Shorter Drug-Tuberculosis Regimen: Implications with High Fluoroquinolone Resistant Tuberculosis and Weak Healthcare Systems
